VYGR VOYAGER THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VOYAGER THERAPEUTICS INC reported revenue of $3.17M (down 39.1% from a year earlier), net income of −$24.5M and diluted EPS of −$0.40; over the last four quarters revenue was $34.5M and net income −$108M; for the fiscal year ended December 2025 revenue was $40.4M, down 49.5% on the year before.
VYGR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $40.4M, gross profit n/a, operating income −$132M, net income −$120M (margin -296.5%), EPS −$2.04
- Fiscal year ended Dec 2024: revenue $80.0M, gross profit n/a, operating income −$83.3M, net income −$65.0M (margin -81.3%), EPS −$1.13
- Fiscal year ended Dec 2023: revenue $250M, gross profit n/a, operating income $122M, net income $132M (margin 52.9%), EPS $2.97
- Fiscal year ended Dec 2022: revenue $40.9M, gross profit n/a, operating income −$50.8M, net income −$46.4M (margin -113.4%), EPS −$1.21
- Fiscal year ended Dec 2021: revenue $37.4M, gross profit n/a, operating income −$73.6M, net income −$71.2M (margin -190.3%), EPS −$1.89
VYGR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.17M (down 39.1% year over year), net income −$24.5M, EPS −$0.40
- Quarter ended Mar 31, 2026: revenue $2.59M (down 59.9% year over year), net income −$27.9M, EPS −$0.47
- Quarter ended Dec 31, 2025 (from the annual report): revenue $15.3M (up 144.3% year over year), net income −$27.4M, EPS −$0.47
- Quarter ended Sep 30, 2025: revenue $13.4M (down 45.7% year over year), net income −$27.9M, EPS −$0.47
- Quarter ended Jun 30, 2025: revenue $5.20M (down 82.4% year over year), net income −$33.4M, EPS −$0.57
- Quarter ended Mar 31, 2025: revenue $6.47M (down 66.8% year over year), net income −$31.0M, EPS −$0.53
- Quarter ended Dec 31, 2024 (from the annual report): revenue $6.28M (down 93.0% year over year), net income −$34.5M, EPS −$0.59
- Quarter ended Sep 30, 2024: revenue $24.6M (up 433.8% year over year), net income −$9.04M, EPS −$0.16
- Quarter ended Jun 30, 2024: revenue $29.6M (up 509.5% year over year), net income −$10.1M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue $19.5M (down 87.0% year over year), net income −$11.3M, EPS −$0.20
- Quarter ended Dec 31, 2023 (from the annual report): revenue $90.1M (up 5914.1% year over year), net income $56.4M, EPS $1.13
- Quarter ended Sep 30, 2023: revenue $4.61M (down 88.8% year over year), net income −$25.9M, EPS −$0.59
- Quarter ended Jun 30, 2023: revenue $4.85M (up 581.6% year over year), net income −$22.2M, EPS −$0.51
- Quarter ended Mar 31, 2023: revenue $150M (up 22769.3% year over year), net income $124M, EPS $2.94
- Quarter ended Dec 31, 2022 (from the annual report): revenue −$1.55M (down 105.5% year over year), net income −$23.6M, EPS −$0.60
- Quarter ended Sep 30, 2022: revenue $41.1M (up 2672.3% year over year), net income $17.6M, EPS $0.45
- Quarter ended Jun 30, 2022: revenue $712K (down 47.5% year over year), net income −$19.1M, EPS −$0.50
- Quarter ended Mar 31, 2022: revenue $658K (down 89.9% year over year), net income −$21.3M, EPS −$0.56
- Quarter ended Dec 31, 2021 (from the annual report): revenue $28.1M, net income $5.71M, EPS $0.16
- Quarter ended Sep 30, 2021: revenue $1.48M, net income −$25.1M, EPS −$0.67
VYGR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$132M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$15.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $77.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$12.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$53.5M, share buybacks n/a, dividends $0.00 per share
VYGR balance sheet
- Jun 30, 2026: cash $35.8M, total assets $198M, total liabilities $43.4M, shareholders' equity $154M
- Mar 31, 2026: cash $43.3M, total assets $219M, total liabilities $45.7M, shareholders' equity $174M
- Dec 31, 2025: cash $65.3M, total assets $252M, total liabilities $56.2M, shareholders' equity $196M
- Sep 30, 2025: cash $45.1M, total assets $288M, total liabilities $68.5M, shareholders' equity $220M
- Jun 30, 2025: cash $43.9M, total assets $322M, total liabilities $78.2M, shareholders' equity $244M
- Mar 31, 2025: cash $74.8M, total assets $353M, total liabilities $80.5M, shareholders' equity $273M
- Dec 31, 2024: cash $71.4M, total assets $393M, total liabilities $93.3M, shareholders' equity $300M
- Sep 30, 2024: cash $113M, total assets $426M, total liabilities $95.7M, shareholders' equity $330M
What is VYGR's revenue?
VOYAGER THERAPEUTICS INC reported $34.5M of revenue over its last four quarters, through June 30, 2026.
Is VYGR profitable?
No. VOYAGER THERAPEUTICS INC lost $108M over the last four quarters.
What is VYGR's EPS?
Diluted earnings per share over the last four quarters were −$1.81; −$0.40 in the latest quarter.